Compound ID | 2163
CF-296
Class: Bacteriophage and/or bacteriophage-derived product
| Agent Type: | Natural product; Direct acting; Bacteriophage or bacteriphage-derived product; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | Cell wall-active agent |
| Target Pathogen: | Active against Staphylococcus aureus |
| Combined with other compounds: | Yes |
| Description: | Peptidoglycan hydrolysing enzyme; exhibits substantial killing alone, but also synergises with daptomycin and vancomycin |
| Year first mentioned: | 2021 |
| Highest development stage: | Preclinical |
| Development status: | Experimental |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.